Normosang 25 mg/ml Concentrate for solution for infusion.
PDF Leaflet Revision Date: 02 June 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acute attacks of hepatic porphyrias.
Dosage (summary)
3 mg/kg once daily for 4 days, max 250 mg/day.
Special Populations
- Elderly patients
- Children and adolescents
Pregnancy & Breastfeeding
Limited data; not recommended during lactation.
Key Drug Interactions
- Oestrogens
- Barbiturates
- Steroids
Contraindications
- Hypersensitivity to hemin
- Safety not established in children and nursing women
Common side effects
- Infusion site pain
- Infusion site swelling
- Thrombophlebitis
Counselling Points
- Administer slowly over 30 mins
- Flush vein post-infusion
- Record product details for traceability
Serious warnings
- Risk of thrombosis
- Monitor for iron overload
- Potential for infection transmission
Important Disclaimer
The Normosang 25 mg/ml Concentrate for solution for infusion. professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
